

    BOXED WARNING: WARNING:  EMBRYO≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  FETAL≠I-OSE_Labeled_AE   TOXICITY≠I-OSE_Labeled_AE 

  WARNING: EMBRYO-FETAL TOXICITY

    IMPAVIDO may cause  fetal≠B-OSE_Labeled_AE   harm≠I-OSE_Labeled_AE .  Fetal≠B-NonOSE_AE   death≠I-NonOSE_AE  and  teratogenicity≠B-NonOSE_AE  occurred in animals administered miltefosine at doses lower than the recommended human dose.  Do not administer IMPAVIDO to  pregnant≠B-Not_AE_Candidate  women. Obtain a serum or urine  pregnancy≠B-NonOSE_AE  test in females of reproductive potential prior to prescribing IMPAVIDO. Females of reproductive potential should be advised to use effective contraception during IMPAVIDO therapy and for 5 months after therapy   [see Contraindications (  4.1  ), Warnings and Precautions (  5.1  ), Use in Specific Populations (  8.1  ,   8.8  ) and Nonclinical Toxicology (  13.1  )]  .  



   EXCERPT:   WARNING: EMBRYO-FETAL TOXICITY



   See full prescribing information for complete boxed warning.  



   IMPAVIDO may cause fetal harm. Fetal death and teratogenicity, occurred in animals administered miltefosine at doses lower than the recommended human dose.  Do not administer IMPAVIDO to pregnant women. Obtain a serum or urine pregnancy test in females of reproductive potential prior to prescribing IMPAVIDO.    



   Advise females of reproductive potential to use effective contraception during therapy and for 5 months after therapy (  4.1  ,   5.1  ,   8.1  ,   8.8  ,   13.1  ).  
